Company profile
UK company 11317849, incorporated on 18 April 2018.
LUNAC Therapeutics | Anticoagulant Discovery
LUNAC Therapeutics are a drug discovery spin-out from University of Leeds, developing next generation oral anti-coagulant therapies.
Company number 11317849
Updated 07 Jul 2026 09:49
Financial period: 1 Jun 2023 to 31 May 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
LUNAC Therapeutics develops anti-coagulant drugs to prevent thrombosis.
A virtual company that is seeking investor funding to pursue development of our anticoagulant drug.
In early stages but soon will happen!
1 Jun 2020 to 30 Nov 2020
no public description
1 Sep 2019 to 31 May 2021
Current treatments for patients who have a risk of forming blood clots are effective but carry a significant increase in the risk of bleeding. Anticoagulants taken by mouth include vitamin-K dependent antagonists (e.g. warfarin), direct thrombin inhibitors and FXa inhibitors [Non-vitamin K Oral Anticoagulants (NOACs)]. Studies have shown that NOACs signif...
